Re:Cognition Health starts Alzheimer’s Trials

Recognitionhealth-logoRe:Cognition Health based at Plymouth Science Park is to start Clinical trials of Axovant’s RVT-101, a compound in development to treat Alzheimer’s disease.

The last drug to be approved to help improve Alzheimer’s patients’ cognition was Donepezil in 2002 so the findings of this trial could be huge. If approved, the drug could be the first approved Alzheimer’s treatment in 14 years.

Re:Cognition Health is the only facility in the South West of England to begin the clinical trial.

Read the full story here…